Skip to main content
$1.20 -$0.01 (-0.8%)

09:43 AM EST on 02/22/24

Karyopharm Therapeutics (NASDAQ:KPTI)

CAPS Rating: 1 out of 5

Current Price $1.20 Mkt Cap $138.6M
Open $1.22 P/E Ratio -0.92
Prev. Close $1.21 Div. (Yield) $0.00 (0.0%)
Daily Range $1.20 - $1.25 Volume 146,884
52-Wk Range $0.62 - $4.87 Avg. Daily Vol. 1,767,346


How do you think NASDAQ:KPTI will perform against the market?

Add Stock to CAPS Watchlist

All Players

25 Outperform
8 Underperform

All-Star Players

1 Outperform
5 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:KPTI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (98.78)
Submitted August 16, 2015

Lots of knowledgeable commenters have been rising to the defense of Karyopharm subsequent to the stock's recent decimation. The plunge came after the company revealed a disproportionate number of cases of sepsis in the selinexor arm of the SOPRA… More

zzlangerhans (98.78)
Submitted March 26, 2015

For a while it's seemed that I've been obligated to be positive about every new biopharma I've analyzed for CAPS. Most of the time, that's been because I've only added the stock to my database after Portefeuille made me buy it for our real life… More


Fools bearish on NASDAQ:KPTI are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about KPTI.


Member Avatar hepanefc (76.49) Submitted: 6/25/2023 11:28:35 PM : Underperform Start Price: $2.02 NASDAQ:KPTI Score: +55.03

Bad profit ratios


Member Avatar charkowicz (< 20) Submitted: 2/21/2021 2:58:29 PM : Outperform Start Price: $14.90 NASDAQ:KPTI Score: -120.34

Institutional ownership is very high as is management's. Key partnerships with large pharma and joint projects validate products and science. Issues are whether they can expand beyond current expertise and also monetize their products.


Member Avatar mdriver78 (66.17) Submitted: 5/20/2020 11:24:25 AM : Outperform Start Price: $17.69 NASDAQ:KPTI Score: -156.40

Last year Karyopharm received FDA approval for a therapy called selinexor as multiple myeloma therapy in patients who have received at least four prior lines but still had refractory disease.
Multiple myeloma is a cancer of plasma cells found in the bone marrow. It’s estimated that 30,000 people are diagnosed with this form of cancer every year in the U.S. alone. There are multiple approved therapies, but it still kills about 13,000 people per year. The disease is often more managed as a chronic condition than cured, with patients hitchhiking to new drugs as old ones stop working.

Selinexor is still relatively new on the market, so its potential as a fifth-line therapy is substantial. The company estimates this market at 6,000 patients per year.

But Karyopharm is working on clinical trials designed to showcase selinexor’s ability as a second- or third-line therapy, which, at 32,000 patients per year, is a substantially larger market. Moreover, multiple myeloma patients tend to stay on their early lines of therapy for longer, meaning it’s an even larger market than just head count.

Karyopharm received data for selinexor in this group earlier this year that it believes support an additional approval with the FDA. It submitted this Supplemental New Drug Application today, meaning the company could now have access to a much larger market upon approval, something that could happen by early next year.
Moreover, Karyopharm is studying selinexor in multiple clinical trials for additional cancer types and even COVID-19! It has submitted an application for this drug in diffuse large B-cell lymphoma (DLBCL) with the FDA expected to respond by June 23, 2020.

But there are even more big catalysts in this small biotech. Karyopharm also expects Phase 3 trial results for selinexor in liposarcoma by the end of the year, and the company is expected to launch a COVID-19 trial soon.

These are big catalysts in a biotech with a market cap of just $1.3 billion. Best of all, the company has plenty of cash, reporting $385 million in cash and investments as of the end of the last quarter, which should be enough to fund it through these big near-term catalysts.


Find the members with the highest scoring picks in KPTI.

Score Leader


alexeys (86.64) Score: +250.55

The Score Leader is the player with the highest score across all their picks in KPTI.

Member Name Member
Call Time
Score Commentary
alexeys 86.64 6/19/2014 Underperform 1Y $41.27 -97.07% +153.48% +250.55 0 Comment
WildShaman 81.24 7/9/2018 Underperform 5Y $18.75 -93.55% +79.79% +173.34 0 Comment
sln 40.59 7/6/2021 Underperform 5Y $10.60 -88.58% +14.62% +103.21 0 Comment
wsmoot8796 77.87 5/4/2023 Underperform 1Y $2.73 -55.69% +22.60% +78.30 0 Comment
XMFFlygal 93.62 6/2/2023 Underperform 5Y $2.24 -45.98% +16.01% +62.00 0 Comment
hepanefc 76.49 6/26/2023 1/30/2024 Underperform 1Y $2.02 -40.10% +14.93% +55.03 1 Comment
ershler 81.18 6/27/2023 Underperform 5Y $1.93 -37.31% +15.00% +52.31 0 Comment
PAGEBOY73 93.71 6/27/2023 Underperform 1Y $1.89 -35.98% +14.24% +50.21 0 Comment
NextGenStock < 20 7/20/2023 Outperform 5Y $1.59 -23.90% +9.48% -33.38 0 Comment
usubanas2 86.12 3/21/2023 Outperform 5Y $3.54 -65.77% +24.64% -90.41 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for KPTI.